IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

GOTHENBURG, SWEDEN / ACCESSWIRE / January 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, January 3, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ...

Related Keywords

Gothenburg ,Vastra Gotalands Lan ,Sweden ,Stockholm ,Japan ,China ,Gunnar Olsson ,Arvid Carlsson ,Propharma Group ,Michaelj Fox Foundation ,Nasdaq Stockholm ,New Drug Application ,Briefing Book ,Nobel Laureate ,Integrative Screening Process ,Irlab Therapeutics ,Noirlab ,S Fda ,Reatment For Parkinson 39s Disease ,Phase Iii ,Arkinson 39s Disease ,Rlab Therapeutics Ab ,